Neuronetics Past Earnings Performance
Past criteria checks 0/6
Neuronetics's earnings have been declining at an average annual rate of -3.1%, while the Medical Equipment industry saw earnings growing at 12% annually. Revenues have been growing at an average rate of 6.2% per year.
Key information
-3.1%
Earnings growth rate
8.6%
EPS growth rate
| Medical Equipment Industry Growth | 8.9% |
| Revenue growth rate | 6.2% |
| Return on equity | -388.3% |
| Net Margin | -50.1% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Neuronetics, Inc. (NASDAQ:STIM) Analysts Just Slashed Next Year's Revenue Estimates By 12%
Nov 18
A Piece Of The Puzzle Missing From Neuronetics, Inc.'s (NASDAQ:STIM) 28% Share Price Climb
Nov 05Investors Give Neuronetics, Inc. (NASDAQ:STIM) Shares A 60% Hiding
Aug 13Here's Why Shareholders May Want To Be Cautious With Increasing Neuronetics, Inc.'s (NASDAQ:STIM) CEO Pay Packet
May 24The Neuronetics, Inc. (NASDAQ:STIM) First-Quarter Results Are Out And Analysts Have Published New Forecasts
May 09Neuronetics: Reality Set In
May 09Market Cool On Neuronetics, Inc.'s (NASDAQ:STIM) Revenues Pushing Shares 36% Lower
May 08Neuronetics (NASDAQ:STIM) Has Debt But No Earnings; Should You Worry?
May 01Even With A 26% Surge, Cautious Investors Are Not Rewarding Neuronetics, Inc.'s (NASDAQ:STIM) Performance Completely
Mar 17Neuronetics: Modest Improvements Are Not Enough
Jan 30Neuronetics, Inc. (NASDAQ:STIM) Soars 61% But It's A Story Of Risk Vs Reward
Dec 19Neuronetics, Inc.'s (NASDAQ:STIM) Shares Not Telling The Full Story
Jun 21Does Neuronetics (NASDAQ:STIM) Have A Healthy Balance Sheet?
May 10Neuronetics: Growth To Capture, But Fairly Priced
Sep 06Is Neuronetics (NASDAQ:STIM) Using Debt Sensibly?
Sep 06Neuronetics gets FDA nod for its D-Tect accessory product for use to treat depression
Aug 29Neuronetics GAAP EPS of -$0.39 beats by $0.02, revenue of $16.3M beats by $0.84M , revises FY guidance
Aug 02Neuronetics stock soars 30% as FDA clears NeuroStar system for anxious depression
Jul 19Is Neuronetics (NASDAQ:STIM) A Risky Investment?
Jun 08Revenue & Expenses Breakdown
How Neuronetics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 73 | -36 | 73 | 9 |
| 30 Jun 24 | 72 | -32 | 72 | 9 |
| 31 Mar 24 | 73 | -28 | 72 | 9 |
| 31 Dec 23 | 71 | -30 | 73 | 10 |
| 30 Sep 23 | 69 | -33 | 73 | 10 |
| 30 Jun 23 | 68 | -31 | 73 | 11 |
| 31 Mar 23 | 67 | -37 | 75 | 10 |
| 31 Dec 22 | 65 | -37 | 75 | 9 |
| 30 Sep 22 | 62 | -37 | 73 | 8 |
| 30 Jun 22 | 59 | -37 | 71 | 7 |
| 31 Mar 22 | 57 | -34 | 67 | 7 |
| 31 Dec 21 | 55 | -31 | 63 | 8 |
| 30 Sep 21 | 56 | -27 | 59 | 8 |
| 30 Jun 21 | 55 | -22 | 52 | 9 |
| 31 Mar 21 | 50 | -23 | 48 | 8 |
| 31 Dec 20 | 49 | -27 | 51 | 9 |
| 30 Sep 20 | 51 | -31 | 53 | 11 |
| 30 Jun 20 | 55 | -35 | 58 | 13 |
| 31 Mar 20 | 61 | -34 | 62 | 14 |
| 31 Dec 19 | 63 | -29 | 60 | 14 |
| 30 Sep 19 | 61 | -28 | 60 | 12 |
| 30 Jun 19 | 59 | -26 | 58 | 10 |
| 31 Mar 19 | 55 | -26 | 55 | 9 |
| 31 Dec 18 | 53 | -24 | 52 | 8 |
| 30 Sep 18 | 49 | -23 | 48 | 8 |
| 30 Jun 18 | 46 | -22 | 44 | 8 |
| 31 Mar 18 | 43 | -17 | 39 | 7 |
| 31 Dec 17 | 40 | -16 | 36 | 8 |
| 31 Dec 16 | 34 | -11 | 29 | 8 |
Quality Earnings: STIM is currently unprofitable.
Growing Profit Margin: STIM is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: STIM is unprofitable, and losses have increased over the past 5 years at a rate of 3.1% per year.
Accelerating Growth: Unable to compare STIM's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: STIM is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (12.9%).
Return on Equity
High ROE: STIM has a negative Return on Equity (-388.26%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/23 19:52 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Neuronetics, Inc. is covered by 6 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Michael Gorman | BTIG |
| William Plovanic | Canaccord Genuity |
| David Turkaly | JMP Securities |